July 7, 2006 is a key date in the life of Didier Tabary. With two investment funds, he bought ought Filorga, a pioneering laboratory in developing anti-age medical devices. “The beauty revolution was booming. Filorga simply demanded to expand,” remembers the 41-year old president of the company. After completing studies at the École Supérieure de Commerce, his first professional stint in Honduras gave him the bug for travel. After this he joined Bourjois in 1994. A good move: he went to Latin America and Korea in 1998 and to Italy three years later to set up subsidiaries. In 2006, he came across Filorga. The lab’s spearhead, NCTF 135, the first ready-to-use mesotherapy kit made to EC standards, was a hit with beauty specialists, with to date over one million treatments (hyaluronic acid plus cocktail of actives). In October 2007 Filorga’s cosmesotherapy range was born, a range for the general public resulting from Filorga’s medical expertise, whose core formula is injectable NCTF, transported in chronospheres to better reach the dermis and act on wrinkles, radiance, firmness and skin quality.
Optim-Eyes? Out of stock two months after it came out in October 2008.
Sleep and Peel? One jar sold every five minutes. After strong development in Europe and Asia (2009 growth +40% and turnover doubled between 2006 and2009), all that remains is to win over the United States and Japan.
Good trips are on the horizon.
BP
Beyond Beauty MAG #28